Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.
BACKGROUND
Anidulafungin is one of three available intravenous echinocandins that plays an important role in the treatment of serious fungal infections. Currently, anidulafungin is approved for the treatment of esophageal candidiasis, candidemia and other invasive Candida infections including intra-abdominal abscesses and peritonitis.


METHODS
This paper covers a comprehensive review of anidulafungin.


RESULTS
The reader will be provided the most recent data available regarding the pharmacology, pharmacokinetics, in vitro activity and clinical utility of anidulafungin for the treatment of serious fungal infections.


CONCLUSIONS
Echinocandin antifungals, such as anidulafungin, are now considered first line for the treatment of candidemia and invasive candidiasis, particularly in critically ill patients or those who have previously received azole therapy. Anidulafungin has potent in vitro activity against Candida and Aspergillus species, predictable pharmacokinetics that does not require dosage adjustment, few drug interactions and is well tolerated. Because of these favorable characteristics, anidulafungin is an important addition to our antifungal armamentarium.
Kuti
Effie L
EL
University of Connecticut School of Pharmacy, Storrs, CT, USA.
Kuti
Joseph L
JL
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D054714:Echinocandins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D054714:Echinocandins; D000077612:Anidulafungin
Diagn Microbiol Infect Dis. 2003 Feb;45(2):131-5
12614985
Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68
16304173
Antimicrob Agents Chemother. 2005 Feb;49(2):767-9
15673762
Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9
19546367
Antimicrob Agents Chemother. 2009 Jan;53(1):112-22
18955538
J Clin Microbiol. 2008 Aug;46(8):2620-9
18579718
J Electron Microsc (Tokyo). 2002;51(4):247-55
12227555
Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506
20385855
J Antibiot (Tokyo). 1990 Apr;43(4):433-7
2141016
Antimicrob Agents Chemother. 2008 May;52(5):1873-5
18347112
Drug Resist Updat. 2007 Jun;10(3):121-30
17569573
Clin Infect Dis. 2005 Nov 15;41(10):1455-60
16231257
J Clin Pharmacol. 2007 Mar;47(3):305-14
17322142
Antimicrob Agents Chemother. 2008 Jul;52(7):2305-12
18443110
Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56
19029327
Ther Clin Risk Manag. 2007 Mar;3(1):71-97
18360617
Clin Infect Dis. 2009 Mar 1;48(5):503-35
19191635
Antimicrob Agents Chemother. 2005 Nov;49(11):4795-7
16251335
J Clin Pharmacol. 2005 Dec;45(12):1373-82
16291712
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):732-5
2850912
Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):573-81
17696807
J Clin Microbiol. 2009 Jun;47(6):1942-6
19386851
N Engl J Med. 2007 Jun 14;356(24):2472-82
17568028
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50
18070979
J Clin Microbiol. 1998 Oct;36(10):2950-6
9738049
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):304-9
18545153
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6
17420211
J Electron Microsc (Tokyo). 2005 Jan;54(1):67-77
15695488
Antimicrob Agents Chemother. 2005 Dec;49(12):5146-8
16304189
Antimicrob Agents Chemother. 2009 Sep;53(9):4035-9
19596890
Int J Antimicrob Agents. 2009 Sep;34(3):282-3
19369040
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4
16048988
Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7
19770284
J Clin Microbiol. 2009 Oct;47(10):3323-5
19710267
Antimicrob Agents Chemother. 2006 Sep;50(9):3160-1
16940118
J Clin Microbiol. 2006 Mar;44(3):760-3
16517851
Clin Microbiol Infect. 2009 Mar;15(3):274-9
19210699
Antimicrob Agents Chemother. 2008 Jan;52(1):321-8
17938191
Antimicrob Agents Chemother. 2008 Jul;52(7):2673-6
18443124
Antimicrob Agents Chemother. 2005 Feb;49(2):830-2
15673781
Antimicrob Agents Chemother. 2010 Jan;54(1):426-39
19884370
Pharmacotherapy. 2009 Jan;29(1):17-30
19113794
Antimicrob Agents Chemother. 1997 Apr;41(4):863-5
9087508
Antimicrob Agents Chemother. 2006 Nov;50(11):3695-700
16954319
Antimicrob Agents Chemother. 1994 Jul;38(7):1480-9
7979276
Antimicrob Agents Chemother. 1996 Aug;40(8):1811-6
8843286
Antimicrob Agents Chemother. 2004 Jun;48(6):2021-4
15155194
Curr Med Res Opin. 2009 Feb;25(2):385-93
19192983
J Infect Dis. 2004 Oct 15;190(8):1464-71
15378439
J Clin Pharmacol. 2004 Jun;44(6):590-8
15145966
Antimicrob Agents Chemother. 1997 Nov;41(11):2471-9
9371352
Clin Infect Dis. 2004 Sep 15;39(6):770-5
15472806
Antimicrob Agents Chemother. 2008 Apr;52(4):1556-8
18212099
Curr Opin Pharmacol. 2007 Oct;7(5):491-7
17616480
Antimicrob Agents Chemother. 1998 Apr;42(4):873-8
9559799
Antimicrob Agents Chemother. 2009 May;53(5):2005-13
19237647
J Clin Pharmacol. 2005 Feb;45(2):227-33
15647416
J Clin Pharmacol. 2007 Apr;47(4):461-70
17389555
Antimicrob Agents Chemother. 2009 Feb;53(2):794-5
19064891
Antimicrob Agents Chemother. 2003 Apr;47(4):1376-81
12654673
Antimicrob Agents Chemother. 2010 Feb;54(2):943-4
19933794
J Antimicrob Chemother. 2010 Feb;65(2):374-6
19996140
Antimicrob Agents Chemother. 2006 Feb;50(2):632-8
16436720
Clin Infect Dis. 2004 Aug 1;39(3):309-17
15306996
Antimicrob Agents Chemother. 1998 Nov;42(11):2898-905
9797223
J Clin Microbiol. 2010 May;48(5):1592-9
20335424
Antimicrob Agents Chemother. 2009 Jun;53(6):2382-91
19307368
Antimicrob Agents Chemother. 2007 May;51(5):1616-20
17307976
Antimicrob Agents Chemother. 2005 Feb;49(2):721-7
15673756
Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55
11557479
Drug Resist Updat. 2011 Jun;14(3):164-76
21353623
Antimicrob Agents Chemother. 2000 Dec;44(12):3381-8
11083644
Expert Opin Drug Saf. 2006 Nov;5(6):751-8
17044802
J Med Chem. 1995 Aug 18;38(17):3271-81
7650681